Skip to main navigation Skip to search Skip to main content

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

  • A. Dierig
  • , M. Hoelscher
  • , S. Schultz
  • , L. Hoffmann
  • , A. Jarchow-MacDonald
  • , E. M. Svensson
  • , L. Te Brake
  • , R. Aarnoutse
  • , M. Boeree
  • , T. D. McHugh
  • , L. M. Wildner
  • , X. Gong
  • , P. P. J. Phillips
  • , L. T. Minja
  • , N. Ntinginya
  • , S. Mpagama
  • , A. Liyoyo
  • , R. S. Wallis
  • , M. Sebe
  • , F. A. Mhimbira
    • B. Mbeya, M. Rassool, L. Geiter, Y. L. Cho, N. Heinrich (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

10   Link opens in a new tab Citations (Scopus)
116 Downloads (Pure)

Fingerprint

Dive into the research topics of 'A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science